Fundraising FoxFrazier Life Sciences — 2021 Investments
7 investments dated 2021 · listed companies and verified rows first · show all
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Board seatJames TopperJames W. Brush· per SEC Form D
Co-investorsBain Capital Life SciencesLongitude CapitalViking GlobalBlackRockCasdin CapitalFranklin Templeton+6 more
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardTadataka Yamada(Director)Cindy Cole(Director)inNancy Hong(Director)
Board seatPatrick HeronAditya Kohli· per SEC Form D
Co-investorsCompanion FundCorrelation VenturesDigitalis VenturesRiverVest Venture Partners
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
William L. Rust(Executive Officer, Director, Promoter)inCarole Welsch(Executive Officer)inGi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)
Board seatJames N. Topper· per SEC Form D
Co-investorsMaryland TEDCOTEDCOJDRF T1D Fund
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
PartnerJames N. Topper· led
Co-investorsDecheng CapitalBiotechnology Value FundOrbiMed
Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
BiotechHealthtechSan Francisco, US
Uri Lopatin(CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)
BoardJ. Jay Lobell(Director)
Co-investorsY CombinatorForesite CapitalKhosla Ventures
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersGV (Google Ventures)JDRF T1D FundLAVLifeforce Capital+6 more
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsAvoro Capital AdvisorsLongitude CapitalWellington ManagementHercules Capital, Inc.OrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.